Vivo Capital LLC Grows Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Vivo Capital LLC lifted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 47.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,482,727 shares of the biotechnology company's stock after buying an additional 801,528 shares during the quarter. Astria Therapeutics comprises approximately 1.6% of Vivo Capital LLC's holdings, making the stock its 13th largest position. Vivo Capital LLC owned 5.60% of Astria Therapeutics worth $19,067,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. AJOVista LLC acquired a new position in Astria Therapeutics during the 4th quarter valued at $51,000. Jump Financial LLC bought a new stake in shares of Astria Therapeutics in the third quarter valued at about $111,000. Finally, Affinity Asset Advisors LLC grew its position in Astria Therapeutics by 53.7% during the third quarter. Affinity Asset Advisors LLC now owns 1,000,300 shares of the biotechnology company's stock worth $7,462,000 after buying an additional 349,425 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Up 6.3 %

Astria Therapeutics stock traded up $0.60 during mid-day trading on Thursday, hitting $10.17. 677,934 shares of the company were exchanged, compared to its average volume of 965,867. Astria Therapeutics, Inc. has a 1-year low of $4.26 and a 1-year high of $16.90. The business has a fifty day moving average of $12.34 and a 200 day moving average of $9.51. The company has a market capitalization of $558.47 million, a PE ratio of -4.38 and a beta of 0.81.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08). Research analysts expect that Astria Therapeutics, Inc. will post -1.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. HC Wainwright decreased their price objective on Astria Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, April 23rd. Wedbush restated an "outperform" rating and issued a $17.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 26th. Finally, Jefferies Financial Group raised their price objective on shares of Astria Therapeutics from $22.00 to $27.00 and gave the stock a "buy" rating in a report on Monday, March 25th.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.